Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
Annexon announced a virtual investor event on November 3, 2026 at 11:00 AM ET focused on the Phase 3 ARCHER II trial of vonaprument in geographic atrophy. Management will cover trial design, patient demographics, and communication strategy ahead of anticipated 15-month and 24-month results beginning in Q4 2026. Retina specialist Roger Goldberg will join to discuss the geographic atrophy treatment landscape.
Key figures
- Event date
- November 3, 2026, 11:00 AM ET
- Data timing
- 15-month and 24-month ARCHER II results beginning Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.